4.6 Article

SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells

Journal

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpendo.00207.2012

Keywords

somatostatin receptor 2; insulin; glucagon; electrophysiology; exocytosis

Funding

  1. Canadian Institutes of Health Research [MOP-106435]
  2. Medical Research Council [GO801995, GO700222/81696]
  3. Wellcome Trust [095331/Z/11/Z, 95101/Z/10/Z]
  4. Department of Health (National Institute for Health Research Biomedical Research Centre's funding scheme)
  5. MRC [G0801995] Funding Source: UKRI
  6. Medical Research Council [G0801995] Funding Source: researchfish
  7. Wellcome Trust [095531/Z/11/Z] Funding Source: researchfish

Ask authors/readers for more resources

Kailey B, van de Bunt M, Cheley S, Johnson PR, MacDonald PE, Gloyn AL, Rorsman P, Braun M. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am J Physiol Endocrinol Metab 303: E1107-E1116, 2012. First published August 28, 2012; doi:10.1152/ajpendo.00207.2012.-Somatostatin-14 (SST) inhibits insulin and glucagon secretion by activating G protein-coupled somatostatin receptors (SSTRs), of which five isoforms exist (SSTR1-5). In mice, the effects on pancreatic beta-cells are mediated by SSTR5, whereas alpha-cells express SSTR2. In both cell types, SSTR activation results in membrane hyperpolarization and suppression of exocytosis. Here, we examined the mechanisms by which SST inhibits secretion from human beta- and alpha-cells and the SSTR isoforms mediating these effects. Quantitative PCR revealed high expression of SSTR2, with lower levels of SSTR1, SSTR3, and SSTR5, in human islets. Immunohistochemistry showed expression of SSTR2 in both beta- and alpha-cells. SST application hyperpolarized human beta-cells and inhibited action potential firing. The membrane hyperpolarization was unaffected by tolbutamide but antagonized by tertiapin-Q, a blocker of G protein-gated inwardly rectifying K+ channels (GIRK). The effect of SST was mimicked by an SSTR2-selective agonist, whereas a SSTR5 agonist was marginally effective. SST strongly (>70%) reduced depolarization-evoked exocytosis in both beta- and alpha-cells. A slightly weaker inhibition was observed in both cell types after SSTR2 activation. SSTR3- and SSTR1-selective agonists moderately reduced the exocytotic responses in beta- and alpha-cells, respectively, whereas SSTR4- and SSTR5-specific agonists were ineffective. SST also reduced voltage-gated P/Q-type Ca2+ currents in beta-cells, but normalization of Ca2+ influx to control levels by prolonged depolarizations only partially restored exocytosis. We conclude that SST inhibits secretion from both human beta- and alpha-cells by activating GIRK and suppressing electrical activity, reducing P/Q-type Ca2+ currents, and directly inhibiting exocytosis. These effects are mediated predominantly by SSTR2 in both cell types.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available